Investigational drug · Phase 2
KHK4951
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "KHK4951"
First trial start
2024
Jan 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KHK4951", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema (DME)
- Neovascular Age-Related Macular Degeneration (nAMD)
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "KHK4951" as an intervention, largest first.
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaPivotal-lookingActive, not recruiting
Kyowa Kirin Co., Ltd.Industry
NCT06116916 · 185 participants · Start Jan 9, 2024 · Primary completion Oct 31, 2026
Drug: KHK4951; Aflibercept Injection · For: Diabetic Macular Edema (DME)
Sites: Mesa, Arizona; Tucson, Arizona; Arcadia, California · 87 sites in all
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationPivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT06116890 · 170 participants · Start Jan 31, 2024 · Primary completion Jun 3, 2026
Drug: KHK4951; Aflibercept Injection · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Mesa, Arizona; Tucson, Arizona; Arcadia, California · 84 sites in all
- A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular DegenerationPivotal-lookingTerminated
Kyowa Kirin Co., Ltd.Industry
NCT04594681 · 116 participants · Start Sep 16, 2020 · Primary completion Aug 26, 2022
Drug: Placebo; KHK4951 · For: Healthy Volunteers; Wet Age-related Macular Degeneration
Sites: Fukuoka, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.
Shirian JD, Shukla P, Singh RP · Eye (Lond) 2025
Also in development for Diabetic Macular Edema (DME)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- RemigromigEYE103, RestoretPhase 33 trials
EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- RC28-EPhase 31 trial
RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.